TY - JOUR
T1 - How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure
AU - Newman, Emily
AU - Kamanu, Chukwuemezie
AU - Gibson, Gregory
AU - Brailovsky, Yevgeniy
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/9
Y1 - 2024/9
N2 - Purpose of Review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352–380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to ≤ 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications. Recent Findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Summary: Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.
AB - Purpose of Review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352–380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to ≤ 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications. Recent Findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Summary: Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.
KW - Guideline directed Medical therapy
KW - Guidelines
KW - Heart failure reduced ejection fraction
KW - Medications
KW - Systolic heart failure
UR - http://www.scopus.com/inward/record.url?scp=85200382913&partnerID=8YFLogxK
U2 - 10.1007/s11886-024-02101-x
DO - 10.1007/s11886-024-02101-x
M3 - Article
AN - SCOPUS:85200382913
SN - 1523-3782
VL - 26
SP - 995
EP - 1003
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 9
ER -